Pfizer Expects 2024 Adjusted EPS Of $2.75-$2.95 Compared To Prior Guidance Of $2.45-$2.65 And Consensus Of $2.65
Portfolio Pulse from Benzinga Newsdesk
Pfizer has updated its 2024 adjusted EPS guidance to $2.75-$2.95, higher than previous guidance and consensus. The company anticipates $10.5 billion in revenue from Comirnaty and Paxlovid, and expects 9%-11% operational revenue growth excluding these products and including Seagen's contribution.
October 29, 2024 | 10:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer has increased its 2024 adjusted EPS guidance to $2.75-$2.95, surpassing previous guidance and consensus estimates. The company projects $10.5 billion in revenue from Comirnaty and Paxlovid, and expects 9%-11% operational revenue growth excluding these products and including Seagen's contribution.
Pfizer's increased EPS guidance and revenue projections indicate strong financial performance expectations, likely boosting investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100